超声观察辛伐他丁对原发性高血压左室重量的作用

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (9): 1001-1004.

超声观察辛伐他丁对原发性高血压左室重量的作用

张平洋, 邓又斌¹, 杨好意¹, 潘敏¹, 毕小军¹

南京医科大学附属南京第一医院心血管超声科, 南京 210001, 江苏;
¹华中科技大学同济医学院附属同济医院超声影像科, 武汉 430030, 湖北

收稿日期:2005-06-09 修回日期:2005-08-31 发布日期:2020-11-22

Ultrasonic study on effects of simvastatin on left ventricular mass in patients with essential hypertension

ZHANG Ping-yang, DENG You-bin¹, YANG Hao-yi¹, PAN Min¹, BI Xiao-jun¹

Department of Cardialvascular Ultrasonography, First Hospital of Nanjing Affiliated to Nanjing Medical University, Nanjing 210001, Jiangsu, China;
¹Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China

Received:2005-06-09 Revised:2005-08-31 Published:2020-11-22
Contact: ZHANG Ping-yang, male, professor, PHD/MD ( medicine doctorate), tutor of graduate student, president of department of cardialvascular ultrasonography, engaged in ultrasonography and ultrasonic study of medi cine. Tel:025-85223915 86624213-8698 E-mail:Zhpy28 @hotmail.com

摘要/Abstract

摘要： 目的: 研究辛伐他丁对原发性高血压(EH) 患者左室重量(LVM) 的影响。方法: 采用随机、对照、单盲法将50 例EH 患者分为两组:联合用药组(口服辛伐他丁和利尿剂)、利尿药组(口服利尿剂) 各25 例, 超声观察治疗12 周前后患者左室重量指数(LVMI)。25 例正常人作为对照组, 不予任何治疗。结果: 与正常对照组(88.79±22.73 g^。m^-2) 相比, 治疗前两组患者的LVMI 均增大(133.61±31.02,118.04±39.62 g^。m^-2, P <0.01 或0.0001), 血压增高, 而年龄、血脂、血糖无显著性差异(P >0.05)。治疗后联合用药组患者的LVMI 显著减小(91.07±16.01 g^。m^-2 VS 133.61±31.02 g^。m^-2, P <0.01),而利尿药组LVMI 无明显改变;联合用药组患者的左室重量指数变化率(LVMICH) 较利尿药组显著增大(P <0.05), 而血压、血糖、血脂无显著差异。治疗前后两组患者的血压下降至正常, 但血脂、血糖无显著性变化。相关分析显示, 联合用药组患者的左室重量指数变化率与血压、血糖和血脂的变化率间无有意义相关性(P >0.05)。结论: 辛发他丁可以抑制EH 患者左室重量增加, 这一作用不依赖血压和血脂、血糖等改变独立存在。

关键词: 超声, 辛伐他丁, 原发性高血压, 左室重量

Abstract: AIM: To evaluate the effect of simvastatin on the left ventricular mass in patients with essential hypertension (EH).METHODS: 50 patients with hypertension without severe complication were randomly divided into two treatment groups:combination treatment group and hydragogue group, and 25 normal subjects without any treatment were taken as the control.The 25 patients in combination treatment group were given simvastatin and hydragogue for 12 weeks while the other patients in hydragogue group were given hydragogue during the same time.The left ventricular mass was examined from ultrasonography in all patients before and after treatment.RESULTS: The left ventricular mass index (LVMI) was higher in the two treatment groups of patients (133.61±31.02, 118.04±39.62 g^。m^-2) than that in the control group (88.79±22.73 g^。m^-2) before treatment (P <0.01, 0.0001, respectively) while the blood pressure was higher.There was no significantly difference in age, serum concentrations of total cholesterol or triglyceride, sugar and blood pressure between the two treatment groups and the control group (P >0.05).There was no significant difference in all variables between the two treatment groups before treatment.After treatment, the LVMI was decreased (133.61±31.02 vs 91.07±16.01 g^。m^-2, P <0.01) in the combination treatment group while there was no significant change in LVMI in the hydragogue group compared with the control group.The blood pressure in the two treatment groups was decreased to the normal.Compared with hydragogue group, the change of LVMI was higher in the combination group though the serum concentrations of total cholesterol, triglyceride or sugar were not significantly different.No significant change in serum concentrations of total cholesterol, triglyceride or sugar was found during treatment in the two groups.The change of LVMI did not correlate with the change of blood pressure, serum concentrations of total cholesterol, triglyceride or sugar in the combination treatment group(P >0.05).CONCLUSION: Being independent of the changes of serum concentrations of total cholesterol, triglyceride or sugar and blood pressure, simvastatin can inhibit the increase of left ventricularmass in patients with essential hypertension.

Key words: simvastatin, essential hypertension, left ventricular mass, ultrasonography

中图分类号:

R972

张平洋, 邓又斌, 杨好意, 潘敏, 毕小军. 超声观察辛伐他丁对原发性高血压左室重量的作用[J]. 中国临床药理学与治疗学, 2005, 10(9): 1001-1004.

ZHANG Ping-yang, DENG You-bin, YANG Hao-yi, PAN Min, BI Xiao-jun. Ultrasonic study on effects of simvastatin on left ventricular mass in patients with essential hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 1001-1004.

[1]	叶森, 陈彦震, 赖丽萍, 钟凌剑, 余长章. 超声与X线引导椎体成形术穿刺进针路径的手术疗效及安全性对比研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 551-557.
[2]	刘馨, 冷玉芳, 张学红, 张莉莉, 张梦婕, 瞿珊珊, 谢建琴, 王一青. 纳布啡在超声引导下经阴道穿刺取卵术中的应用及对胚胎质量和妊娠结局的影响[J]. 中国临床药理学与治疗学, 2021, 26(9): 1042-1047.
[3]	范剑峰，方译，郑春华. 沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(7): 810-814.
[4]	朱林佳，原少斐，上官宗校，慈晓，赵仁国，李玉苹. 超声-微泡介导的microRNA-449a通过调节Notch1对肺癌细胞的生长抑制作用[J]. 中国临床药理学与治疗学, 2019, 24(12): 1385-1393.
[5]	陈战巧，钟柳美，李霞，应锦河. 脂质型人工泪液对行超声乳化吸除术的白内障患者术后干眼的临床研究[J]. 中国临床药理学与治疗学, 2018, 23(12): 1380-1385.
[6]	金岳龙，王林红，朱丽君，梁伟，段滢,杨松，陈燕春，赵祥海，沈冲，姚应水. 一氧化氮合酶基因多态性与常用降压药疗效的关联研究[J]. 中国临床药理学与治疗学, 2017, 22(5): 538-544.
[7]	郭道遐, 陈燕春, 王林红, 鲁玮, 沈冲, 杨松, 赵祥海, 金岳龙, 姚应水. 高迁移率族蛋白1基因多态性与中国南方农村常用高血压药物疗效的关系[J]. 中国临床药理学与治疗学, 2014, 19(7): 766-771.
[8]	王莉, 单毓强. 爱全乐等氧气雾化吸入对减轻术后咳嗽、咳痰及降低肺部感染的临床研究[J]. 中国临床药理学与治疗学, 2013, 18(8): 910-913.
[9]	胡红珍, 刘萍, 罗永红, 项良春. 聚焦超声和LEEP刀治疗宫颈柱状上皮异位的疗效对比[J]. 中国临床药理学与治疗学, 2013, 18(5): 561-564.
[10]	尹芳, 李云飞, 黄继汉, 李禄金, 郑青山. 长效降压药动态血压试验设计与定量分析方法实例介绍[J]. 中国临床药理学与治疗学, 2012, 17(6): 666-671.
[11]	李敏利, 朱人敏, 林勇, 杨妙芳, 张晓华. 超声引导下无水乙醇硬化治疗老年及老年前期肝囊肿的临床研究[J]. 中国临床药理学与治疗学, 2012, 17(4): 448-452.
[12]	邱日想, 王燕莉, 陈洋娣, 林雁, 杨凤, 陈智毅. 低强度超声联合托泊替康诱导人肝癌细胞凋亡的研究[J]. 中国临床药理学与治疗学, 2012, 17(12): 1384-1388.
[13]	徐承华, 杨玉雯, 曹蘅. β₁肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响[J]. 中国临床药理学与治疗学, 2011, 16(12): 1414-1418.
[14]	彭翠英, 周翠兰, 贺庆芝. 湖南汉族人群TNF-α基因-308G/A多态与原发性高血压相关性研究[J]. 中国临床药理学与治疗学, 2011, 16(1): 57-60.
[15]	李真, 王燕娥, 王娇, 朱皓, 刘俊. 非洛地平对高血压患者QT间期离散度和左室重构的影响[J]. 中国临床药理学与治疗学, 2010, 15(5): 561-564.